Plain-English translation of NCT06498986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether works safely and effectively when given together with in people with advanced non-small cell lung cancer. Osimertinib is an existing lung cancer medication, and the researchers want to see if adding this new treatment improves results. The study will enroll about 40 participants.
People with advanced lung cancer that has specific genetic changes (EGFR mutations) currently have limited treatment options. Researchers believe combining this new medication with an existing treatment may work better to slow or stop cancer growth.
You likely qualify if…
You likely don't qualify if…
You would take the medication combination for cycles of 3 weeks at a time. If your cancer responds well to the treatment, you can continue receiving additional cycles. Throughout the trial, doctors will monitor how well the medication works and watch for any side effects through regular visits and tests. Treatment continues until your cancer progresses, side effects become too severe, or you and your doctor decide to stop for another reason.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Enrollment target
~40 participants
Started
July 2024
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sa Xiao, PHD
Shanghai East Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.